Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
AVUS vs IBB: how they differ
AVUS and IBB hold 1% of their weight in the same names, and IBB returned more over the year.
Avantis U.S. Equity ETF and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, AVUS and IBB hold 1% of their money in the same securities at the same weight.
| Holding | AVUS | IBB |
|---|---|---|
| Gilead Sciences Inc | 0.45% | 6.85% |
| Amgen Inc | 0.20% | 7.84% |
| Vertex Pharmaceuticals Inc | 0.14% | 8.09% |
| Regeneron Pharmaceuticals Inc | 0.11% | 4.91% |
| United Therapeutics Corp | 0.09% | 1.74% |
| Exelixis Inc | 0.07% | 1.03% |
| Biogen Inc | 0.06% | 2.47% |
| Illumina Inc | 0.03% | 2.07% |
| Incyte Corp | 0.03% | 1.75% |
| Neurocrine Biosciences Inc | 0.02% | 1.30% |
| Moderna Inc | 0.02% | 1.99% |
| Medpace Holdings Inc | 0.02% | 0.95% |
| Only in AVUS | Only in IBB |
|---|---|
| NVIDIA Corp 5.49% | Argenx SE 3.76% |
| Apple Inc 5.37% | Alnylam Pharmaceuticals, Inc. 3.12% |
| Microsoft Corp 3.85% | Natera, Inc. 2.89% |
| Amazon.com Inc 3.68% | Insmed, Inc. 1.79% |
| Alphabet Inc 2.42% | BeOne Medicines Ltd. 1.77% |
| Micron Technology Inc 2.40% | Roivant Sciences Ltd. 1.43% |
| Meta Platforms Inc 2.21% | Ascendis Pharma A/S 1.29% |
| Alphabet Inc 1.94% | Genmab A/S 1.12% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| AVUS Avantis U.S. Equity ETF | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Avantis | iShares |
| What it is | U.S. Equity | Biotechnology |
| Total return, 1 year | +21.6% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +4.1 pts | +24.0 pts |
| Expense ratio | 0.15% | 0.44% |
| Already in the S&P 500 | 84.4% | 35.6% |
| Holdings | 1875 | 248 |
AVUS in plain words
AVUS is an index equity fund tracking the U.S. Equity. Over the year to Sep 11, 2026 it returned +21.6% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.15% a year. By its holdings filed for May 31, 2026, 84% of the fund by weight is stocks the S&P 500 also holds, across 1875 positions, with the top ten at 29.7%.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, AVUS or IBB?
- In the year to Sep 12, 2026, with distributions reinvested, AVUS returned +21.6% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, AVUS or IBB?
- AVUS charges 0.15% a year and IBB charges 0.44%, so AVUS is cheaper. Fees come from each fund's prospectus.
- How much do AVUS and IBB overlap with the S&P 500?
- By their latest filed holdings, 84% of AVUS and 36% of IBB by weight is stocks the S&P 500 already holds. Between the two funds, 1% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, AVUS against IBB, data as of Sep 12, 2026. https://etfiq.com/compare/any/AVUS-IBB Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources